AEON Biopharma (AEON) Change in Accured Expenses (2021 - 2025)

AEON Biopharma has reported Change in Accured Expenses for 5 years, with the latest figure at $331000.0 in Q4 2025.

• Quarterly Change in Accured Expenses fell 81.17% year-over-year to $331000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.2 million (changed 0.0% YoY) and the FY2025 annual result came in at -$2.2 million, down 55.02% from the prior year.
• Change in Accured Expenses retreated to $331000.0 in Q4 2025 per AEON's latest filing, from $481000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.0 million in Q1 2023 and troughed at -$3.2 million in Q1 2024.
• A 5-year average of $4740.3 and a median of $106970.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 3614.41% in 2023, down 2537.94% in 2023.
• Over 5 years, Change in Accured Expenses stood at $564585.0 in 2021, then slumped by 168.9% to -$389000.0 in 2022, then slumped by 337.28% to -$1.7 million in 2023, then jumped by 203.35% to $1.8 million in 2024, then tumbled by 81.17% to $331000.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $331000.0, $481000.0, and -$982000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.